Chief Operating Officer · Travere Therapeutics, Inc. (TVTX)

Neil McFarlane

A named executive officer of Travere Therapeutics in every fiscal year CompBrief holds from FY2016 to FY2018. Every figure below is printed as the company filed it and cited to the filing it came from.

Total disclosed compensation, FY2018

$2,345,084

Salary $494,188Stock awards $584,480

FY2017: $2,186,978

3rd of 6 named executive officers at Travere Therapeutics by FY2018 total.

6 named officers on file for Travere Therapeutics, FY2018

Neil McFarlane’s pay file — $29

  • 3 fiscal years of pay, line by line
  • 4 equity grants, each cited to its filing
  • TVTX’s disclosed peer group of 16 companies

A PDF and a CSV sent to your email. Every row is cited to its filing.

One-time report. No refunds.

See an example →

Velarion Intel · free for 3 days · no card

See how Travere Therapeutics’s whole pay program stands against its peers

  • Travere Therapeutics’s company dashboard and its AI-written, board-ready brief, every figure cited to the filing
  • Peer-group intelligence, custom peer reruns and governance screens
  • Every other company we cover, with alerts when they file
Start my free trial on TVTX→

No card. Nothing is charged, and the trial ends on its own.

Compensation figures as of the proxy filed April 4, 2019 (DEF 14A).

Free

Get Neil McFarlane’s pay history as a PDF, right here and by email

The PDF adds what this page leaves out: up to 10 years of pay, a peer comparison, and the board on one page. Two emails at most, nothing else.

Neil McFarlane compensation by year

Travere Therapeutics Summary Compensation Table · all 3 fiscal years held
In US dollars, as Travere Therapeutics reports it. Most recent year shaded. Totals are the company’s disclosed totals.
ComponentFY2016FY2017FY2018
Salary$179,952$480,938$494,188
Bonus$100,000$0$0
Stock awards$792,900$442,279$584,480
Option awards$1,271,544$1,006,830$1,009,997
Non-equity incentive$84,115$162,717$228,436
Pension and deferred compensation$0$0$0
All other$3,065$94,214$27,893
Total$2,431,576$2,186,978$2,345,084

Each year as stated in that year's proxy. A dash means the company reported no figure in that column. Source: Travere Therapeutics, Inc. DEF 14A filed April 4, 2019, accession 0001193125-19-097950, and prior-year filings. Open the filing on EDGAR.

How this page was built: the Travere Therapeutics, Inc. filed document, accession 0001193125-19-097950. Every figure is read from that document and cited to the page and table it appears in. Filed April 4, 2019.

$2.4M
$2.2M
$2.3M
FY16
FY17
FY18
SalaryBonusNon-equity incentiveStock awardsOption awardsAll other

Equity holdings

unvested awards at FY2018 year-end
TypeUnvested unitsValue at year-endExercise price
PSU20,000$452,600—
PSU11,125$251,759—
PSU10,500$237,615—
PSU10,500$237,615—
PSU3,750$84,863—
PSU2,546$57,616—
Option63,000—$25.25
Option56,250—$17.44
Option30,000—$17.62

Per the Outstanding Equity Awards at Fiscal Year-End table in Travere Therapeutics, Inc.'s FY2018 proxy; value at the fiscal year-end close, as the company printed it.

Travere Therapeutics’s named executive officers, FY2018

as the company reported each
Named executive officerRoleFY2018 total
Stephen AselagePresident and Chief Executive Officer$4,602,287
Noah RosenbergChief Medical Officer$2,403,083
Neil McFarlane · this pageChief Operating Officer$2,345,084
Laura ClagueSenior Vice President and Chief Financial Officer$1,860,308
William RoteSenior Vice President and Head of Research and Development$1,618,525
Elizabeth ReedSenior Vice President, General Counsel and Corporate Secretary$1,581,261

The full Travere Therapeutics compensation record

free company brief

This page is one person within Travere Therapeutics's record. The company brief lists every named executive, each linking to their own page.

Compensation, the day it’s disclosed

The CompBrief Daily Digest lists the newest executive and director compensation disclosures as companies file them.

How this record is built

Every figure on this page is one figure from a public SEC filing, printed as the filing states it and cited to the document. Compensation totals are Travere Therapeutics's own disclosed totals, not summed by Velarion. Insider transactions are read from Form 4 filings and cover every line filed since the most recent proxy. Nothing is estimated by Velarion; where the company does not disclose a value the cell reads "—", and a section appears only where the company discloses the data. Corrections: records@velarion.ai.

Neil McFarlane's compensation dossier · One-time report. No refunds.